AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of Natera's management will present at the 2024 Leerink Partners Healthcare Crossroads Conference on Thursday, May 30, 2024 at 8:40 a.m. PT (11:40 a.m. ET). A live webcast may be accessed through the investor relations section of the Natera website at i...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will present new data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024. The presentations feature data across a variety of indications, including breast cancer,...
Natera, Inc. (NASDAQ:NTRA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - President, Clinical Diagnostics Alex Aleshin - General Manager Oncology and Chief Medical Officer Conference Call Participants Dan Brennan - TD Cowen Tejas Savant - Morgan Stanley Puneet Souda ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024. Recent Strategic and Financial Highlights Achieved positive cash flow of approximately $3.0 million1 in the first quarter of 2024. Generated total revenues of $367.7 million in the first quarter of 202...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to detect recurrence early in patients with early-stage breast cancer. The full study can be found here. The...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on May 9, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera's Fi...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test. This comes at a critical time for the healthcare industry, helping physicians navigate patient care given nationwide shortages of Rho(D) immune globulin therapy (RhIg). Natera's test can be performed as early a...
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.